Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04006236 · ClinicalTrials.gov registry record · NA
Infants Fed Extensively Hydrolyzed Casein-Based Infant Formulas
A NA study of Infant Development, sponsored by Abbott Nutrition.
- Completed
- Registry status
- NA
- Development phase
- 245
- Enrollment target
- 17
- Study locations
NCT04006236: Completed NA study of Infant Development, sponsored by Abbott Nutrition.
NCT04006236 is a NA study of Infant Development that has completed, run by Abbott Nutrition. The registered enrollment target is 245 participants, below the 395-participant average among 30 other Infant Development trials with a reported enrollment target (38% lower). The trial reports 17 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04006236, a NA study of Infant Development, has completed, sponsored by Abbott Nutrition.
- COMPLETED
- Registry status
- NA
- Development phase
- 245 participants
- Enrollment target
- 17
- Study locations
Study Summary
This is a randomized, controlled, double-blind, multicenter parallel study to evaluate the growth, tolerance and compliance of healthy infants fed infant formulas with extensively hydrolyzed casein protein.
Primary Outcome
Interval weight gain per day
Conditions Studied
Interventions
- OTHER Experimental Infant Formula
- OTHER Control Infant Formula
Study Locations (17)
Ohio
- Pediatric Associates of Fairfield, Inc. - Fairfield
- Institute of Clinical Research, LLC - Mentor
- The Cleveland Pediatric Research Center, LLC - Middleburg Heights
Texas
- Ventavia Research Group, Llc - Fort Worth
- Ventavia Research Group - Houston
- Ventavia Research Group, LLC - Plano
Arizona
- MedPharmics, LLC - Phoenix
- Watching Over Mothers & Babies - Tucson
Georgia
- Paramount Research Solutions - College Park
Kentucky
- Springs Medical Research - Owensboro
Louisiana
- MedPharmics, LLC - Metairie
Mississippi
- MedPharmics, LLC - Gulfport
Nebraska
- Quality Clinical Research Inc - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 245 participants |
| Start Date | 2019-08-05 |
| Est. Completion | 2021-09-20 |
| Phase | NA |
What the finished NCT04006236 record still lists
NCT04006236 is an interventional study that assigns participants to a tested intervention. The registered 245 participants enrollment target is mid-sized for trials with a published cap, below the 395-participant average among 30 other Infant Development trials with a reported enrollment target (38% lower).
The record links to 1 condition, with Infant Development appearing as the primary indexed condition, and to 2 interventions - of which Experimental Infant Formula is the first listed.
NCT04006236 lists 17 locations in 12 states (Ohio, Texas, Arizona).
Frequently Asked Questions
What is clinical trial NCT04006236 about?
NCT04006236 is a clinical study titled "Infants Fed Extensively Hydrolyzed Casein-Based Infant Formulas". This is a randomized, controlled, double-blind, multicenter parallel study to evaluate the growth, tolerance and compliance of healthy infants fed infant formulas with extensively hydrolyzed casein protein.
What is the current status of trial NCT04006236?
This trial is currently completed. It is a NA study. The enrollment target is 245 participants. The study started on 2019-08-05. Estimated completion is 2021-09-20.
What conditions does trial NCT04006236 study?
This clinical trial studies the following conditions: Infant Development.
What interventions are being tested in trial NCT04006236?
The interventions under investigation include: Experimental Infant Formula (OTHER), Control Infant Formula (OTHER).
Who is sponsoring clinical trial NCT04006236?
This trial is sponsored by Abbott Nutrition, which has 89 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04006236 being conducted?
This trial has 17 study locations across Arizona, Georgia, Kentucky, Louisiana, Mississippi. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Infant Development
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04006236's enrollment target sits among peer trials
245 8th of 30 higher than 23 of 30 other Infant Development trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Infant Development trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Walnuts as an Infant Solid Food for Health
RECRUITING · NA
-
Infant-Maternal Partnership and Cognitive Training Study for Preterm Infants
RECRUITING · NA
-
The Impact of Music Medicine on Preterm Brain Development and Behavior
RECRUITING · NA
-
Intervening With Opioid-Dependent MothersMothers and Infants
RECRUITING · NA
-
Investigating Baby Behavior and Family Technology Use Study
RECRUITING · NA
-
Investigating Fit and Satisfaction of the Prone Positioner
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03645928 · 245 participants · Phase 2
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
- NCT04718168 · 245 participants · NA
GORE® ENFORM Biomaterial Product Study
- NCT05145127 · 245 participants · Phase 3
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
- NCT05446259 · 245 participants
Degenerative Cervical Myelopathy Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI